Neoplasms, Unknown Primary × Endocrine × Clear all
NCT04459273 2026-02-05

FAPI PET RDRC

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
26 enrolled
NCT02012699 2026-01-22

iCaRe2

University of Nebraska

Recruiting
999,999 enrolled
NCT05461430 2025-09-15

TraveraRTGx

Travera Inc

Recruiting
200 enrolled
NCT04985357 2024-11-25

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Travera Inc

Withdrawn
NCT03896958 2020-12-04

PIONEER

SpeciCare

Unknown
1,000 enrolled
NCT00004074 2013-02-28

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled
NCT00005842 2013-02-11

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
NCT00020579 2012-03-15

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
75 enrolled
NCT00005860 2011-04-26

Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

National Cancer Institute (NCI)

Phase 1 Completed